DRRX : Summary for DURECT Corporation - Yahoo Finance

U.S. Markets closed

DURECT Corporation (DRRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.98+0.01 (+1.02%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.97
Bid0.90 x 3000
Ask1.06 x 5500
Day's Range0.97 - 0.98
52 Week Range0.96 - 2.00
Avg. Volume468,378
Market Cap135.81M
PE Ratio (TTM)-3.90
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire2 hours ago

    DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference Call

    CUPERTINO, Calif., Feb. 24, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2016 financial results press release, you are invited to listen to a conference call ...

  • Zacks Small Cap Research9 days ago

    DRRX: Update on DUR-928 Development Program

    By Grant Zeng, CFA NASDAQ:DRRX Among Durect’s (NASDAQ:DRRX) multiple candidates, DUR-928 may be the most promising one in our view because this compound has the potential to target multiple indications ...

  • PR Newswire25 days ago

    DURECT Corporation Announces Update on DUR-928 Development Program

    CUPERTINO, Calif., Jan. 30, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today provided an update on the DUR-928 development program.  DUR-928, our Epigenetic Regulator Program's lead product candidate, is an endogenous, small molecule, new chemical entity (NCE), which may have broad applicability in several metabolic diseases such as nonalcoholic steatohepatitis (NASH) and other liver conditions, and in acute organ injuries such as acute kidney injury (AKI). An abstract for this study has been accepted and data from the study will be presented at the International Liver Congress™ 2017 organized by the European Association for the Study of the Liver (EASL) in Amsterdam, April 19-23, 2017.